TRxADE HEALTH, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDS research report →
Companywww.trxadehealth.com
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement.
- CEO
- Surendra K. Ajjarapu
- IPO
- 2014
- Employees
- 8
- HQ
- Land O'Lakes, FL, US
Price Chart
Valuation
- Market Cap
- $13.28M
- P/E
- -0.07
- P/S
- 0.03
- P/B
- 0.05
- EV/EBITDA
- 0.07
- Div Yield
- 125.16%
Profitability
- Gross Margin
- 78.97%
- Op Margin
- -9634.92%
- Net Margin
- -9204.60%
- ROE
- -131.03%
- ROIC
- -60.37%
Growth & Income
- Revenue
- $431.61M · 315766.16%
- Net Income
- $-41,512,264,000 · -457999.72%
- EPS
- $-2.70 · -200.37%
- Op Income
- $-43,507,142,000
- FCF YoY
- -100624.96%
Performance & Tape
- 52W High
- $44.56
- 52W Low
- $3.69
- 50D MA
- $7.54
- 200D MA
- $9.04
- Beta
- 2.17
- Avg Volume
- 61.78K
Get TickerSpark's AI analysis on MEDS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 25, 24 | Shankar Hariharan | other | 0 |
| Jul 25, 24 | Shankar Hariharan | other | 0 |
| Jul 25, 24 | Shankar Hariharan | other | 356,480 |
| Jul 25, 24 | Shankar Hariharan | other | 1,916,816 |
| Jul 25, 24 | Narasimhan Mani | other | 0 |
| Jul 25, 24 | Narasimhan Mani | other | 1,357,538 |
| Jan 5, 24 | AJJARAPU SURENDRA K | other | 10,000 |
| Jan 5, 24 | Patel Prashant | other | 10,000 |
| Jan 5, 24 | Patel Prashant | other | 150,000 |
| Jan 5, 24 | AJJARAPU SURENDRA K | other | 150,000 |
Our MEDS Coverage
We haven't published any research on MEDS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MEDS Report →